Dare Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Dare Bioscience, Inc. (DARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.07% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-26
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-06-30 was 3.11%, a 257.47% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.65%, a 184.48% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-09-30 was 0.97%, a 36.62% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-06-30 was 0.87%, a 27.94% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.07%, a 1.45% decline from fiscal 2024.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.13%, a 16.01% increase from fiscal 2023.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.56%, a 78.00% increase from fiscal 2022.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.00%, a 198.51% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.07% 10-K · filed 2026-03-26 | |||
| 2024-12-31 | 4.13% 10-K · filed 2026-03-26 | |||
| 2023-12-31 | 3.56% 10-K · filed 2025-03-31 | |||
| 2022-12-31 | 2.00% 10-K · filed 2024-03-28 | |||
| 2022-06-30 | 3.11% 10-Q · filed 2022-08-09 | 1.90% 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | 1.65% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.67% 10-K · filed 2023-03-30 | |||
| 2021-09-30 | 0.97% 10-Q · filed 2021-11-10 | 0.66% 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 0.87% 10-Q · filed 2021-08-12 | 0.64% 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 0.58% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 0.82% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 0.71% 10-Q · filed 2020-11-12 | 0.82% 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 0.68% 10-Q · filed 2020-08-12 | 0.82% 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | 0.86% 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | 2.44% 10-K · filed 2021-03-30 | |||
| 2019-09-30 | 2.58% 10-Q · filed 2019-11-12 | 2.58% 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | 2.09% 10-Q · filed 2019-08-14 | 2.58% 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | 2.70% 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | 2.52% 10-K · filed 2020-03-27 | |||
| 2018-09-30 | 2.90% 10-Q · filed 2018-11-13 | 2.90% 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | 2.76% 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | 2.52% 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | 1.85% 10-K · filed 2019-04-01 | |||
| 2017-09-30 | 2.26% 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | 1.80% 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | 1.80% 10-Q · filed 2017-05-12 | |||
| 2016-06-30 | 1.20% 10-Q · filed 2017-08-14 | |||
| 2015-09-30 | 1.70% 10-Q · filed 2016-11-03 | |||
| 2013-09-30 | 1.08% 10-Q · filed 2014-11-13 | |||
| 2013-06-30 | 1.09% 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |